文献速递鼻科

EXHANCE-3:氟替卡松呼气递送系统治疗慢性鼻窦炎伴或不伴鼻息肉的队列研究

EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps.
PubMed 文献 · Rhinology · 2020-01-01

EXHANCE-3 是一项前瞻性、多中心、12 周单臂研究,评估氟替卡松呼气递送系统(EDS-FLU)372 μg 每日两次治疗中重度慢性鼻窦炎伴或不伴鼻息肉的安全性和有效性。共纳入 705 例难治性受试者(603 例 CRSsNP,102 例 CRSwNP),结果显示超过 90% 患者报告改善,SNOT-22 评分显著下降,伴和不伴鼻息肉患者改善程度相似,且安全性良好。

要点

  • EDS-FLU 372 μg 每日两次可显著改善难治性 CRS 患者的客观和主观指标。
  • 伴和不伴鼻息肉患者的 SNOT-22 改善程度相似(-23.7 与 -24.4)。
  • EDS-FLU 总体耐受良好,安全性特征与传统鼻喷激素相似。

核心结论

  • EDS-FLU 372 μg 每日两次治疗伴或不伴鼻息肉的慢性鼻窦炎安全、耐受良好,并在广泛客观和主观指标上产生显著改善。

研究设计与样本

  • 前瞻性、多中心、12 周、单臂研究,在美国 38 个中心进行,评估 EDS-FLU 372 μg 每日两次治疗中重度 CRS 伴或不伴鼻息肉。
  • 共纳入 705 例难治性受试者,其中 603 例为 CRSsNP,102 例为 CRSwNP。
  • 受试者基线 SNOT-22 约 43,既往鼻喷激素使用率 92.3%,既往手术率 27.5%。

主要发现

  • 超过 90% 的患者在 PGIC 上报告治疗改善。
  • SNOT-22 评分在伴鼻息肉患者中改善 -23.7,在不伴鼻息肉患者中改善 -24.4,两者改善程度相似。
  • 基线 Lund-Kennedy 水肿评分 >0 的患者中,33.3% 的 CRSwNP 患者和 54.8% 的 CRSsNP 患者水肿完全消退。
  • CRSwNP 患者中,48% 至少一侧鼻孔息肉消除,63% 息肉分级改善至少 1 分,平均双侧息肉分级从 2.9 降至 1.6,研究定义的手术指征减少。
  • EDS-FLU 总体耐受良好,安全性特征与传统鼻喷激素治疗 CRS 时相似。

临床怎么用

  • 对于传统鼻喷激素治疗不足的中重度 CRS 患者,可考虑使用 EDS-FLU 372 μg 每日两次以改善症状和客观指标。
  • EDS-FLU 可能降低 CRSwNP 患者的研究定义手术指征,但需结合临床判断。

局限性

  • 本研究为单臂设计,缺乏对照组,无法直接比较 EDS-FLU 与常规鼻喷激素或其他治疗的疗效差异。
  • 研究周期为 12 周,长期疗效和安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhaled nasal corticosteroid sprays (INS) are often inadequate to treat chronic rhinosinusitis (CRS). The exhalation delivery system with fluticasone (EDS-FLU; XHANCE®) may improve outcomes in CRS by increasing medication delivery to target superior/posterior anatomic sites. This study assessed safety and efficacy of EDS-FLU in a large population with moderate-to-severe CRS with or without nasal polyps (CRSwNP, CRSsNP). METHODS: Prospective, multicenter, 12-week, single-arm study of EDS-FLU 372 Â#181;g twice daily (BID) at 38 U.S. sites. Safety was assessed by adverse-event evaluations, nasal endoscopy, and ocular examinations. Efficacy was serially assessed by outcomes including nasal endoscopy (Lund-Kennedy Score, polyp grade), patient- and physician-reported outcomes (22-item Sinonasal Outcome Test [SNOT-22]), study-defined surgical indicator assessment, and Patient Global Impression of Change (PGIC). RESULTS: 705 comparatively refractory subjects were enrolled, 603 CRSsNP and 102 CRSwNP [moderate-to-severely symptomatic; baseline SNOT-22 ~43, high rates of prior INS use (92.3%) and/or prior surgery (27.5%)]. More than 90% reported improvement on treatment by PGIC. SNOT-22 scores improved substantially and similarly in patients with NP (-23.7) and without NP (-24.4). Among patients with baseline Lund-Kennedy edema scores >0, 33.3% (CRSwNP) and 54.8% (CRSsNP) had complete resolution of edema. In CRSwNP patients, 48% had polyp elimination in ?1 nostril, 63% had ?1-point improvement in polyp grade, mean bilateral polyp grade decreased from 2.9 to 1.6, and study-defined surgical eligibility decreased. EDS-FLU was generally well tolerated, with a safety profile similar to conventional INS sprays when used to treat CRS CONCLUSION: EDS-FLU 372 #181;g BID in the treatment of CRS with or without polyps was safe, well-tolerated, and produced substantial improvement across a broad range of both objective and subjective measures.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Sher MR, Steven GC, Romett JL, et al. EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps. Rhinology. 2020. PMID: 31815255. doi:10.4193/Rhin19.124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。